Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.

Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.

View in: PubMed

subject areas

Adult
Anti-HIV Agents
Cost-Benefit Analysis
Darunavir
Drug Combinations
Drug Therapy, Combination
Female
Health Care Costs
HIV Infections
Humans
Lopinavir
Male
Middle Aged
Models, Economic
Prognosis
Quality-Adjusted Life Years
Ritonavir
Sulfonamides
Time Factors
Treatment Outcome
United States

authors with profiles

Kit N. Simpson